33476 Federal Register / Vol. 74, No. 132 / Monday, July 13, 2009 / Notices 

Landing Road, Wilmington, Delaware 

19801, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Thebaine (9333), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import a 

Thebaine derivative for the bulk 

manufacture of controlled substances 

for their customers. The company will 

also import analytical reference 

standards for distribution to their 

customers for research purposes. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

being should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than August 12, 2009. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: July 1, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–16520 Filed 7–10–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 20, 2009, 

Organix Inc., 240 Salem Street, Woburn, 

Massachusetts 01801, made application 

by letter to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of Marihuana 

(7360), a basic class of controlled 

substance listed in schedule I. 

The company plans to manufacture a 

synthetic cannabinol in bulk for sale to 

its customers for research purposes. No 

other activity for this drug code is 

authorized for this registration. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 11, 2009. 

Dated: July 1, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–16521 Filed 7–10–09; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (09–066)] 

Review of U.S. Human Space Flight 

Plans Committee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

announces a meeting of the Review of 

U.S. Human Space Flight Plans 

Committee. The agenda topics for the 

meeting include: 

• Kennedy Space Center Perspective. 

• Constellation projects. 

• Committee subgroup report. 

• Public comment. 

DATES: Thursday, July 30, 2009, 8 a.m.– 

4 p.m. Note: All times listed are local 

times. 

ADDRESSES: Hilton Cocoa Beach 

Oceanfront, Grand Ballroom, 1550 

North Atlantic Avenue, Cocoa Beach, 

Florida 32931, 321–799–0003. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Philip R. McAlister, Office of Program 

Analysis and Evaluation, National 

Aeronautics and Space Administration, 

Washington, DC 20546. Phone 202–358– 

0712. 

SUPPLEMENTARY INFORMATION: The 

meeting will be open to the public up 

to the seating capacity of the room. It is 

imperative that the meeting be held on 

this date to accommodate the 

scheduling priorities of the key 

participants. 

P. Diane Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. E9–16533 Filed 7–10–09; 8:45 am] 

BILLING CODE P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (09–064)] 

Review of U.S. Human Space Flight 

Plans Committee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

announces a meeting of the Review of 

U.S. Human Space Flight Plans 

Committee. The agenda topics for the 

meeting include: 

• Johnson Space Center Perspective. 

• Constellation projects. 

• Committee subgroup report. 

• Public comment. 

DATES: Tuesday, July 28, 2009, 10 a.m.– 

4 p.m. Note: All times listed are local 

times. 

ADDRESSES: South Shore Harbour Resort 

& Conference Center, Crystal Ballroom 

Salon A & B, 2500 South Shore Blvd., 

League City, TX 77573, 800–442–5005. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Philip R. McAlister, Office of Program 

Analysis and Evaluation, National 

Aeronautics and Space Administration, 

Washington, DC 20546. Phone 202–358– 

0712. 

SUPPLEMENTARY INFORMATION: The 

meeting will be open to the public up 

to the seating capacity of the room. It is 

imperative that the meeting be held on 

this date to accommodate the 

mstockstill on DSKH9S0YB1PROD with NOTICES